NovoCure Ltd. NVCR 深 滬
已收盤 01-30 16:00:00 美东时间
12.40
+0.020
+0.16%
華盛通- 最 高12.57
- 今 開12.37
- 成交量 132.02万股
- 最 低 12.24
- 昨 收 12.38
- 總市值 13.89亿
- 52周最高 22.95
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 10.70
- 委 比 11.40%
- 總股本 1.12亿
- 歷史最高 232.76
- 量 比 1.35
- 振 幅 2.67%
- 歷史最低 5.95
- 每 手 1
- 風險率 3.40%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 阿斯麦、美光科技、SanDisk获大行上调目标价；美国银行、富国银行绩后遭多家机构下调目标价
今日重点评级关注：Benchmark：维持TNL Mediagene"投机性买入"评级，目标价从3.5美元升至14美元；康托·菲茨杰拉德：维持Eupraxia Pharmaceuticals"超配"评级，目标价从11美元升至19美元
01-16 10:04
Wedbush Reiterates Neutral on NovoCure, Maintains $18 Price Target
Wedbush analyst David Nierengarten reiterates NovoCure (NASDAQ:NVCR) with a Neutral and maintains $18 price target.
01-15 22:03
美股大行评级 | 高盛上调谷歌目标价从330美元升至375美元；5家大行集体上调Five Below目标价最高至255美元
今日重点评级关注：HC Wainwright & Co.：维持NioCorp Developments"买入"评级，目标价从9.5美元升至11.25美元；摩根士丹利：维持Chewy"超配"评级，目标价从48美元升至51美元
01-14 11:25
Novocure Announces Preliminary 2025 Net Revenues $655.4M Up 8% YoY And Q4 $174.4M Up 8% Vs 2024, With Active Patients And 2026 Milestones Update
Preliminary full year 2025 net revenues of $655 million and fourth quarter net revenues of $174 millionNovocure to present at the 44th Annual J.P. Morgan Healthcare Conference at 9:45 a.m. PST on Wednesday, January 14,
01-12 20:18
电话会总结 ｜ NovoCure(NVCR)2024财年Q4业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据NovoCure业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** - Q4 2024营收1.61亿美元，同比增长21% - 全年2024营收6.05亿美元，同比增长19% - 营收增长主要由法国、德国、日本市场强劲表现以及美国批准率显著改善驱动 **盈利能力：** - Q4毛利率79%，全年毛利率77%，均高于2023年的75% - Q4净亏损6,600万美元（每股亏损0.61美元） - 全年净亏损1.69亿美元（每股亏损1.56美元） **调整后EBITDA：** - Q4调整后EBITDA为300万美元，较202
2025-12-24 12:08
美股大行评级 | 最高350美元！16家大行上调谷歌目标价！Meta遭12家大行下调目标价；潜在涨幅1456.29%！NRX Pharmaceuticals获Ascendiant Capital升目标价至47美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从46美元升至47美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从27美元升至31美元
2025-10-31 10:25
美股大行评级 | 买入！Fermi、Neptune获多家大行首予评级；伯克希尔哈撒韦罕见地获得“卖出”评级；摩根大通上调苹果目标价升至290美元
今日重点评级关注：Guggenheim：上调Neumora Therapeutics评级至"买入"，目标价14美元；韦德布什：上调Fate Therapeutics评级至"跑赢大市"，目标价从5美元升至7美元
2025-10-28 10:08
JP Morgan Maintains Neutral on NovoCure, Lowers Price Target to $23
JP Morgan analyst Jessica Fye maintains NovoCure (NASDAQ:NVCR) with a Neutral and lowers the price target from $25 to $23.
2025-10-27 22:36
Novocure To Present Final Results From Phase 3 METIS Trial Of Tumor Treating Fields Therapy For Brain Metastases From NSCLC At 2025 ASTRO
METIS trial achieved its primary endpoint, showing a statistically significant delay in time to intracranial progression in patients receiving TTFields therapy and best supportive care following stereotactic radiation of the metastasesResults from the METIS trial published in the International Journal of Radiation Oncology Biology and Physics
2025-09-30 04:32
Japan's Ministry Of Health, Labour And Welfare Approves Novocure's Optune Lua For Concurrent Use With PD-1/PD-L1 Inhibitors For Adult Patients With Unresectable Advanced/Recurrent Non-small Cell Lung Cancer Who Have Progressed On Or After Platinum-Based Chemotherapy
Optune Lua is a wearable, portable medical device that produces alternating electric fields known as Tumor Treating Fields (TTFields), which are delivered through non-invasive, wearable arrays. TTFields exert physical
2025-09-15 19:03
